Purpose: To investigate outcomes of manufactured fenestrated and branched endovascular aortic repair (F-BEVAR) endografts based on supraceliac sealing zones to treat pararenal aortic aneurysms and thoracoabdominal aortic aneurysms (TAAAs).
With time, the indications of F-BEVAR were broadened to include more complex aneurysms involving the mesenteric arteries, which required placement of sealing stents in the distal thoracic aorta. Because of the risk of disease progression, which can compromise the repair and its targets, several centers including ours have adopted a policy of planning these procedures using more stable segments for sealing zones above the SMA and celiac axis (CA). 7, 11 The purpose of this study was to analyze the outcomes of F-BEVAR using manufactured stent grafts based on supraceliac sealing zones.
METHODS
This study was a prospective, single-center, nonrandomized trial registered at the www.ClinicalTrials.gov (NCT1937949 and NCT2089607). Participation required informed consent approved by the Institutional Review Board, and compliance with the study inclusion and exclusion criteria (Supplementary Table I , online only). F-BEVAR was performed using manufactured patientspecific or off-the-shelf Cook Zenith (Cook Medical, Inc, Bloomington, Ind) fenestrated and branched stent grafts based on supraceliac sealing zones under physiciansponsored investigational device exemption protocols (number G130030 and G130266). One hundred sixty-nine consecutive patients were enrolled in the study since Food Drug Administration approval of the investigational device exemption in March, 5 2013. Of these, 148 patients underwent device implantation, and 21 await implantation. This report summarizes results from the first 127 patients implanted as of March 30, 2016 who had completed a minimum of 30-day follow-up.
Demographics, clinical characteristics, cardiovascular risk factors, and operative and postoperative variables were collected prospectively and stored on case report forms and MEDIRAVE database. Aneurysm classification was based on extent of aneurysmal disease evaluated by computed tomography angiography (CTA). Clinical comorbidities were assessed using the American Society of Anesthesiology classification and the Society for Vascular Surgery (SVS) comorbidity score system. 12, 13 Early postoperative period was defined as occurring within the first 30 days or within the hospital stay if longer than 30 days. Follow-up consisted of clinical examination, laboratory studies, and imaging before discharge and at 1, 6, and 12 months, and annually thereafter for the first 5 years. Imaging evaluation included CTA or computed tomography without contrast and duplex ultrasound of the renal-mesenteric arteries. All imaging studies were independently evaluated by a dedicated group of vascular radiologists. Clinical data entry and case report forms were independently monitored for compliance with regulatory guidelines. Cause of death was determined by review of death certificates and autopsy reports. Adverse events and causes of death were independently reviewed and adjudicated by a clinical event committee and data safety monitoring board. Results of interim analysis were reported annually to the Federal Drug Administration and to the Institutional Review Board.
Device design. Aneurysm morphology was determined by high-resolution CTA datasets. A minimum proximal sealing zone of at least 25 mm was selected in normal supraceliac aortic segments, defined by parallel aortic wall with no evidence of thrombus, calcium, or diameter enlargement >10%. Options for vessel incorporation were doublewide CA scallops (20 Â 20 mm), large (8 Â 8 mm) or small fenestrations (6 Â 6 mm), and directional branches (8 or 6 mm). Specific device design varied depending on aneurysm extent, vessel angulation, and inner aortic diameter, and included either patient-specific devices with up to five fenestrations or branches or off-the-shelf t-Branch multibranch stent graft (Cook Medical, Inc) ( Supplementary Fig 1, online only) . Selection of design was tailored by the primary investigator (G.S.O.) depending on aneurysm extent and diameter of aortic lumen. For renal targets, fenestrations were preferred. For extent I-III TAAAs, directional renal branches were used if the aortic lumen was large (>40 mm), and vessel orientation was down-going without excessive tortuosity. The most common designs for pararenal aneurysms were three fenestrations and doublewide celiac scallop or four fenestrations. For TAAAs, the most common designs were four fenestrations for type IV and combination of directional branches and fenestrations for type I-III TAAAs ( Supplementary Fig 2, online only) .
Target vessel stenting. Alignment stents were standardized for fenestrations and branches with no alignment stent for doublewide scallops. All fenestrations were aligned using balloon-expandable iCAST covered stents (Maquet Atrium, Hudson, NH 
Recommendation:
The authors recommend to follow a strict clinical care pathway for treatment of complex aneurysms with fenestrated and branched endovascular aortic repair to achieve excellent short-term outcomes.
(C. R. Bard, Inc, Tempe, Ariz), which was reinforced distally by a bare-metal self-expandable stent.
Prevention of spinal cord injury. A standardized protocol was used to prevent spinal cord injury (SCI).
14 This included permissive hypertension, routine cerebrospinal fluid drainage for all patients with stents designed with >2 sealing stents above the CA, staging of extensive TAAAs with prior thoracic endovascular aneurysm repair (TEVAR), intraoperative neuromonitoring, and early limb reperfusion.
Statistical analysis. Data was managed and stored in a Medidata Rave (New York, NY) database and analyzed using SAS v 9.4 software (SAS Institute Inc, Cary, NC). Outcomes were analyzed for pararenal, type IV, and type I-III TAAAs. The SVS reporting standards were used to define technical success, aneurysm sac changes, endoleak, migration, and device integrity. 12, 13 Major adverse events (MAEs) were defined using a composite end point, which included any cause mortality, severe acute kidney injury (>50% decrease in estimated glomerular filtration rate), new-onset dialysis, myocardial infarction, respiratory failure requiring prolonged mechanical ventilation or reintubation, paraplegia, stroke, bowel ischemia requiring surgical resection or intensive medical care, and estimated blood loss >1 L. SCI was classified according to severity of neurologic deficit as none (0), minimal sensory (1), ambulatory with minor motor (2) or nonambulatory able to move against gravity (3a), not able to move against gravity (3b), or no movement (3c). Primary and secondary patency were defined by uninterrupted patency from index procedure until occlusion or any stent reintervention for stenosis and by an occlusion treated by surgical bypass or not suitable to endovascular salvage, respectively. Branch instability was defined as any branch-related death, rupture, occlusion, or reintervention for stenosis, kink, endoleak, or disconnection. Time-dependent outcomes were reported using Kaplan-Meier estimates up to 1-year follow-up because of short follow-up interval. Differences were determined by the log-rank test. 
RESULTS
Clinical characteristics. There were 127 patients enrolled in the study, including 91 male (72%) and 36 female (28%), with mean age of 75 6 10 years (Table I) .
Aneurysm classification was pararenal in 47 (37%), type IV TAAA in 42 (33%), and type I to III TAAA in 38 patients (30%), including five type I, 18 type II, and 15 type III. The maximum aneurysm diameter averaged 59 6 17 mm. Patients in the three groups had similar demographics, cardiovascular risk factors, American Society of Anesthesiology scores, and total SVS scores. History of prior aortic repair was more frequent in patients with type I-III TAAA (55%; P < .001). The most prevalent risk factors were cigarette smoking in 112 patients (88%), hypertension in 110 (87%), hypercholesterolemia in 103 (87%), ischemic cardiomyopathy in 67 (53%), chronic obstructive pulmonary disease in 47 (37%), and stage III to V chronic kidney disease in 22 (17%). Thirty-eight patients (30%) had prior aortic repair.
Stent graft design. Endovascular repair was performed using patient-specific devices in 118 patients (93%) and off-the-shelf t-Branch stent graft in nine (7%). A total of 496 renal-mesenteric arteries (123 CA, 126 SMA, 120 right renal, 120 left renal arteries, 7 other) were incorporated by 352 fenestrations, 125 directional branches, and 19 doublewide scallops with a mean of 3.9 vessels per patient. Among patients treated for pararenal aneurysms, 181 target vessels were incorporated using 160 fenestrations, 19 doublewide scallops, and two directional branches. For type IV TAAAs, there were 165 vessels incorporated by 143 fenestrations (87%) and 22 directional branches (13%), whereas for type I-III TAAAs, there were 150 vessels incorporated by 49 fenestrations (33%) and 101 directional branches (67%). Three patients (2%) had four internal iliac artery branch devices.
Procedure details. All procedures were performed in a hybrid endovascular room with fixed imaging unit using general endotracheal anesthesia (Supplementary  Table II , online only). Cerebrospinal fluid drainage was used in 88 patients (69%) and neuromonitoring in 91 patients (71%). Ninety patients (71%) had total percutaneous transfemoral approach with preclosure technique, and seven required iliac conduits (6%). Total volume of contrast and fluoroscopy time averaged 159 6 55 mL and 81 6 30 minutes, respectively, with higher volume of contrast for TAAAs (P < .001). Technical success was achieved in 99.6% of targeted renal-mesenteric vessels (494 of 496). There were no fenestrations left unstented. Two patients (1.6%) required occlusion of renal artery targets by coil embolization attributable to inadvertent disruptions, which occurred because of small vessel diameter and excessive tortuosity. Estimated blood loss was 477 6 517 mL and was significantly higher for type I-III TAAAs (P ¼ .03). Thirty-one patients (44%) received transfusion of packed red blood cells during the procedure, with more transfusions of packed red blood cells and fresh frozen plasma in patients with type I-III TAAAs (P < .05). (17) 6 (13) 9 (21) 7 (18) .55
Stage III 17 (13) 4 (9) 8 (19) 5 (13) Stage IV 5 (4) 2 (4) 1 (2) 2 (5) Stage V 0 0 0 0 Diabetes mellitus 20 (16) 7 (15) 10 (24) 3 (8) . 15 Congestive heart failure 15 (12) 3 (6) 9 (21) 3 (8) .06
Arrhythmia 12 (9) 3 (6) 7 (17) 2 (5) .15
Stroke/TIA 12 (9) 4 (9) 3 (7) 5 (13) .63
Other medical history (Continued on next page) Total CA 123 (25) 45 (25) 42 (25) 36 (24) .96
Large fenestration 63 (13) 25 (14) 34 (21) 4 (3) <.001
Directional branch 41 (8) 1 (1) 8 (5) 32 (21) <.001
Total SMA 126 (25) 46 (25) 42 (25) 38 (25) 1 Large fenestration 86 (17) 45 (25) 35 (21) 6 (4) <.001
Directional branch 40 (8) 1 (1) 7 (4) 32 (21) <.001
Total R renal artery 120 (24) 45 (25) 38 (23) 37 (25) .91
Small fenestration 98 (20) 45 (25) 35 (21) 18 (12) .01
Total L renal artery 120 (24) 44 (24) 40 (24) 36 (24) Early outcomes. There were no 30-day, in-hospital or aneurysm-related deaths (Table II) . Twenty-seven patients (21%) had MAEs, with identical rates in the three groups. The most common MAEs were decline in estimated glomerular filtration rate $50% in 12 patients (9%), blood loss $1 L in 10 (8%), myocardial infarction in nine (7%), respiratory failure requiring reintubation in four (3%), stroke in four (3%), ischemic colitis in three (2%), and paraplegia in two patients (1.5%). Of the two patients with paraplegia, one had complete recovery, and one was permanent (0.8%). One patient (0.8%) required temporary, new-onset dialysis. None of the patients required tracheostomy.
Forty-five patients (35%) developed any complication, with no difference between groups (Supplementary  Table III , online only). The most common complication was cardiac event in 19 patients (15%), which required percutaneous coronary interventions in two (1.5%). Pulmonary problems occurred in eight patients (6%) and renalfunction deterioration in 14 (11%). Seven patients (6%) had gastrointestinal complications including ischemic colitis in three, pseudomembranous colitis in three (2%), and gastrointestinal bleeding in one. Any SCI occurred in five patients (4%), including the two patients with paraplegia, and other three patients with temporary, reversible paraparesis. Two patients had cauda equina hematomas diagnosed by imaging, which was asymptomatic in one patient and associated with unilateral temporary paraparesis in one patient. Four patients had stroke, which were minor in three patients and major in one.
Late outcomes. Mean follow-up was 9.2 6 7 months (range, 1 to 26), including follow-up >30 days in all patients, >6 months in 79, and >12 months in 34. None of the patients were lost to follow-up. A total of 403 followup CTA studies were analyzed with a mean of 3.2 studies per patient. There were 11 late deaths, all because of nonaortic-related causes, including cardiac events in five patients, respiratory failure in three, and malignancy, subdural hematoma after fall, or indeterminate cause in one patient each. Patient survival at 1 year was 96% 6 2% (CI, 91%-100%, Fig 1) for the entire cohort with no Reinterventions. Reinterventions were needed in 23 patients (18%), including 15 patients (12%) who had aortic-related and eight (6%) who had nonaorticrelated procedures (Supplementary Table IV , online only). Indications for aortic reintervention were treatment of endoleaks in eight patients (two type I, two type II and III, and four type III), target vessel stenosis or kinks in four, iliac stenosis or occlusion in two, and severe aortic stent infolding in one. All aortic reinterventions were performed using percutaneous approach and were technically successful. Nonaortic reinterventions included treatment of access site complications or laparotomy for bowel resection in four patients each. Freedom from aortic-related reintervention was 86% 6 4% (95% CI, 79%-95%) at 1 year (Fig 2) , with no difference (P ¼ .438) for pararenal (90% 6 5%; 95% CI, 81%-100%), type IV (93% 6 5%; 95% CI, 85%-100%), and type I-III TAAAs (71% 611%; 95% CI, 52%-97%).
Endoleaks, sac changes, migration, and integrity issues. Fifty-nine patients (46%) had endoleaks (Supplementary Table V, online only) identified by follow-up CTA, including type I endoleak in three patients (2%), type II endoleak in 43 (34%), type III endoleaks in 10 (8%), and type IV endoleak in one patient. Two patients had type Ic endoleaks because of insufficient distal branch sealing zone. One patient was treated for chronic dissection and had a known type Ia endoleak in the proximal thoracic stent placed at an outside institution, which was revised by proximal arch extension after F-BEVAR ( Supplementary  Fig 3, online only) . All type I endoleaks resolved with reintervention. Type III endoleaks occurred in 10 patients (8%) because of insufficient seal at reinforced fenestrations in eight (6%) or inadequate overlap of aortic component in two (2%). Type II endoleaks were observed in all patients except for two; one who had successful coil embolization.
Clinical data on aneurysm sac changes was analyzed in 111 patients. Sixty-three patients (57%) had stable aneurysm diameter, and 48 patients (43%) had >5-mm decrease in diameter. There were no patients with aneurysm sac enlargement. There were no device migrations, fractures, or other integrity issues.
Target vessel stenosis, kinks, and occlusion. Ten patients (8%) had seven stenoses and four occlusions of target vessels, including one patient with bilateral renal in-stent stenosis. Occlusions were attributed to unrecognized kink in one patient, heparin-induced thrombocytopenia in one, and no identifiable cause in two patients. All occlusions occurred in renal artery stents, with a rate 3% for fenestrations and 5% for directional branches. Primary target vessel patency was 94% 6 1% (95% CI, 94%-98%), and secondary target vessel patency was 97% 6 2% (95% CI, 93%-100%) at 1 year (Fig 3) , with no difference in primary patency (96% 6 1% vs 94% 6 3%; P ¼ .841) or secondary patency (98% 6 1% vs 97% 6 2%; P ¼ .493) for fenestrations vs branches, respectively. For renal targets, primary patency was 94% 6 1% (95% CI, 90%-98%) for fenestrations, and 82% 6 9% (95% CI, 67%-100%) for directional branches (P ¼ .188; Supplementary  Fig 4, online only) . Secondary patency was 97% 6 1% (95% CI, 95%-100%) and 89% 6 6% (95% CI, 80%-100%), respectively (P ¼ .137).
Branch instability. Freedom from branch instability was 93% 6 2% (95% CI, 90%-96%) at 1 year for all targeted vessels (Fig 4) , and was lower for renal targets (89% 6 3%; 95% CI, 84%-94%) compared with CA or SMA targets (93% 6 2%; 95% CI, 93%-100%; P ¼ .024; Supplementary  Fig 5, online only) . There was no difference in freedom from branch instability for fenestrations (93% 6 3%; 95% CI, 87%-100%) compared with directional branches (92% 6 2%; 95% CI, 89%-96%) for all targets at 1-year (P ¼ .509, Supplementary Fig 6, online only) .
Renal function deterioration. Freedom from renal function deterioration was 89% 6 4% (95% CI, 92%-96%) at 1 year ( Supplementary Fig 7, online only) , with no significant difference (P > .05) for patients with pararenal (97% 6 3%, 95% CI, 91%-100%), type IV (8767%, 95% CI, 74%-100%), and type I-III TAAAs (80% 6 8%, 95% CI, 66%-98%). There were no patients on permanent dialysis. Chronic kidney disease staging remained stable in most patients ( Supplementary Fig 8, online only) .
DISCUSSION
This study represents the interim early results of a prospective, nonrandomized analysis of endovascular repair of pararenal or TAAAs using fenestrated and branched stent grafts. A wide range of designs was used to adapt to the patient anatomy, reflecting real-world utilization of branch technology with broader indications including failed aortic repairs, chronic dissections, and variations of four-vessel anatomy. The observations of high technical success (99.6%), no mortality and low rate of MAEs (21%), type Ia endoleak, permanent paraplegia, or temporary dialysis, support the safety and effectiveness of fenestrated and branched stent grafts to treat complex aortic aneurysms, beyond what has already been demonstrated in the U.S. Zenith fenestrated study for juxtarenal aneurysms. 15 This study is unique in that we incorporated the concept of using supraceliac sealing zones even for simpler aneurysms. In the early years of fenestrated endografts (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) , sealing zones were based on healthy aortic segments most often between the renal arteries and SMA. 15 This strategy has been changed because of evidence of late neck enlargement after fenestrated endovascular aortic repair (FEVAR), which may lead to flaring of the uncovered top stent, followed by migration, loss of seal, endoleak, and compromise of target vessels. The most feared complication of TAAA repair remains paraplegia. Some reports have shown remarkably high rates of SCI in up to 50% of patients. 6 Our results are in contrast with these reports. Using a specific protocol ( Supplementary Fig 9, online only) that included selective staged procedures and routine cerebrospinal fluid (CSF) drainage, neuromonitoring, and early limb reperfusion, 4% of our patients developed any SCI and 1.5% had paraplegia, which was permanent in 0.8%. 14 The discrepancies in SCI rates are multifactorial, reflecting differences in definition, learning curve, patient selection, and use of a specific protocols to prevent injury. We defined SCI according to the TEVAR reporting standards using clinical evidence of any motor and sensory deficit and evaluation of ambulatory status. 13 Paraplegia was defined by partial or total motor deficit with nonambulatory status (grade 3a to 3c SCI), whereas paraparesis was defined by minimal sensory deficit or minor motor deficit with ability to walk (grade 1 or 2 SCI). Other recent series have also shown marked improvement in paraplegia rates in the range of 0% to 2.5%. 2, 4, 5, 9, 18 A common factor in these reports is that operators have overcome their steep learning curve and adopted routine adjuncts to optimize collateral spinal network perfusion based on experimental evidence of spinal cord collateral adaptation after staged arterial coverage. 19 During endovascular repair, this can be achieved by proximal TEVAR (Supplementary Fig 10, online only), temporary aneurysm sac perfusion, or intentional coil embolization of intercostal arteries. 2, 18, 20 Other adjuncts are permissive hypertension, early limb reperfusion, and use of neuromonitoring. 4, 5, 14 Our preference has been to use proximal TEVAR because of other potential benefits, notably the staged thrombosis of the aneurysm sac, which may influence postoperative coagulopathy and the systemic inflammatory response that is triggered by extensive TAAA endografting. 21 Most importantly, by performing the proximal TEVAR first, the second operation focuses on placement of the visceral branches and distal extensions, decreasing operative time.
Branch instability, particularly in the renal arteries, continues to be a focus of research. The ideal branch should maintain end-organ perfusion and exclude the aneurysm sac, while minimizing complications. In a landmark publication that included 1679 target vessels, Mastracci et al 3 coined the term branch instability, defined by any branch-related death, rupture, or complication that triggered a reintervention. In that study, freedom from branch instability was 88% at 1 year and 70% at 5 years, which compares favorably with our rate of 93% at 1 year. 3 In our study, we found no difference for fenestrations (92%) vs directional branches (93%), although there was a trend toward lower freedom from branch instability for renal (82%) compared with mesenteric arteries (91%). Several experts propose using fenestrations for all renal arteries because of their low occlusion rates (<2%) compared with directional branches (5%-10%). 3, [22] [23] [24] [25] Martin-Gonzalez et al 23 compared renal fenestrations vs branches in 856 renal arteries and found that occlusion rate was four times higher for branches (9.6% vs 2.3%) after 2 years. 23 However, this report and others have used various types of rigid bridging stent grafts, which may have adversely affected patency rates. We have standardized renal branch constructions by using Viabahn stent grafts coupled with bare-metal self-expandable stents and double antiplatelet therapy. We found lower primary and secondary patency rates for renal arteries compared with mesenteric arteries, and a trend toward lower patency rates for renal branches compared with fenestrations. There was no significant difference in the rate of occlusion for fenestrations (2%) or branches (5%). Our low usage of off-the-shelf multibranched stent grafts reflects a philosophy of maximizing use of renal fenestrations to optimize patency rates. However, the authors recognize that renal fenestrations have greater risk of type III endoleaks, which reaches up to 15%. 9 We also observed type III endoleaks in reinforced fenestrations as one of the most common indications for reintervention. Endovascular aortic repair continues to be plagued by high reintervention rates, although most are done percutaneously. In our study, freedom from any reintervention was 81% and aortic-related reintervention was 86% at 1 year. This is lower than what was reported in the U.S. Zenith Fenestrated Study (91%), but compares favorably with the recent report by Eagleton et al 15 (76%). 9 It is likely that reinterventions will be affected by aneurysm complexity and the number of endovascular components at risk, although we could not identify a statistical difference likely because of the small number of patients and limited follow-up. Although reinterventions are likely less frequent with open repair, this has not yet been determined because open surgical reports lack comprehensive analysis of all types of reinterventions, which should also include reoperations for bleeding, tracheostomy, wound problems, hernias, and other gastrointestinal complications. Coselli et al 26 recently reported a remarkably low rate of freedom from aortic failure of 94% in 15 years, but there were only 198 patients at risk from a cohort of over 3300 patients. In that study, there was not an analysis of freedom from any type of reintervention. The study strengths are the prospective design, data monitoring, independent adjudication of clinical outcomes, and use of standardized protocols to design the aortic stent, select bridging stents, and prevent SCI. Our results reflect a decade of experience after overcoming the learning curve, making it difficult to generalize our outcomes to earlier experiences. Several limitations of our study need to be mentioned. Follow-up is still too short to draw any conclusions about time dependent outcomes, and it is likely that rates of reinterventions, vessel patency, and endoleaks will be affected during longer follow-up.
CONCLUSIONS
F-BEVAR of complex aortic aneurysms continues to evolve with improvements in device design, implantation techniques, and adjunctive maneuvers to decrease mortality and paraplegia. Our study shows high technical success, low rate of MAEs, and no aneurysm rupture, conversion, or mortality, supporting the safety and efficacy of fenestrated and branched endografts using supraceliac sealing zones. 
DISCUSSION
Dr Ronald Dalman (Stanford, Calif). Let me just take a moment to put this presentation into perspective. We just were presented a series of 127 thoracoabdominal aneurysm repairs with no 30-day mortality and one patient requiring temporary renal replacement therapy. This, by historical standards, is a phenomenal outcome, and Dr Oderich and his colleagues are to be congratulated for their achievement.
Dr Ahmad Alsheekh. Thank you for the interesting talk. I would like to ask, were there any differences in the procedural time between different types of aneurysms? Because as I noticed there are differences like in contrast time used between different types of these aneurysms.
Dr Gustavo S. Oderich. There was no difference in procedure time.
Dr Richard Cambria (Boston, Mass). My comments echo that of our program committee chair that it is the understatement of the year to say that these results are absolutely outstanding. And my question for you, Gustavo, is, first, how you defined spinal cord ischemic complications overall. You mentioned one permanent paraplegia. And I would also point out that the results presented here today are really quite a bit different and discrepant from some other information about this technology, for example, the French Cooperative National Study that had mortality and paraplegia rates in the 15% to 20% range. So specifically about the paraplegia, what are your current strategies about staged procedures and so forth to achieve these results?
Congratulations on a really outstanding series. Dr Oderich. Dr Cambria, thank you for your comments and questions. This study reflects our late experience after overcoming the learning curve of fenestrated and branched endografts. The rate of paraplegia, which was defined using a grade 3A or 3C injury according to standardized classification, was 2%, with only one case of permanent paraplegia. There were other three patients with paraparesis, which was temporary in all cases. The overall rate of any spinal cord injury for the entire cohort was 4%, including paraplegia and paraparesis. Paraplegia was defined as a nonambulatory motor deficit using the standardized classification, whereas paraparesis was motor deficit in a patient who was able to walk.
Our protocol for prevention has evolved during these years. We currently stage routinely all type 1 and 2 thoracoabdominal aortic aneurysms. All patients with >4 cm supraceliac coverage undergo routine CSF drainage and neuromonitoring. We have a specific protocol on how to use neuromonitoring intraoperatively. The presence of decrease in motor evoked potentials triggers specific maneuvers to increase CSF drainage and increase mean arterial pressure, and to restore lower extremity perfusion. If changes reverse we complete the procedure. However, if there are persistent changes in motor evoked potentials, we may leave the aneurysm sac temporarily perfused. The reason for our satisfactory results is multifactorial and reflects improved patient selection, surgical techniques, our protocols to reduce spinal cord injury and the excellence of postoperative care by our intensive care unit and nursing staff. Most certainly there are patients who were denied surgery because of exceedingly high medical risk or really unfavorable anatomy from the atherosclerotic debris and the small targets. So I think that the discrepancy in data reflects our team approach that has been dedicated to this therapy for a decade.
Dr Dalman. Gustavo, it is interesting that the renal stability seems to be less than the visceral stability and it is likely due to the geometry, I suppose, of the vessels. Do you want to comment on that? Why you think the difference exists for the renal and visceral branches? Dr Oderich. 
